For the quarter ending 2026-03-31, RAPP has $497,597K in assets. $26,085K in debts. $78,056K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 78,056 | 251,359 | 55,067 | |
| Accounts receivable | 58 | - | - | |
| Short-term investments | 398,726 | 261,667 | 205,380 | |
| Restricted cash | 105 | 105 | 105 | |
| Prepaid expenses and other current assets | 7,750 | 7,528 | 9,690 | |
| Total current assets | 484,695 | 520,659 | 270,242 | |
| Total property and equipment | 4,448 | 4,834 | - | |
| Less accumulated depreciation | 1,930 | 1,718 | - | |
| Property and equipment, net | 2,518 | 3,116 | 3,172 | |
| Operating lease right of use asset, net | 9,327 | 10,480 | 11,047 | |
| Other assets | 1,057 | 1,068 | 1,034 | |
| Total assets | 497,597 | 535,323 | 285,495 | |
| Accounts payable | 6,561 | 3,235 | 3,176 | |
| Accrued expenses and other current liabilities | 8,721 | 8,599 | 6,944 | |
| Operating lease liability | 2,615 | 2,482 | 1,759 | |
| Total current liabilities | 17,897 | 14,316 | 11,879 | |
| Operating lease liability, net of current portion | 8,188 | 9,390 | 10,104 | |
| Total liabilities | 26,085 | 23,706 | 21,983 | |
| Common stock, 0.001 par value 500,000,000 shares authorized at march 31, 2026 and december 31, 2025 47,807,453 shares and 47,772,567 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 48 | 48 | 37 | |
| Additional paid-in capital | 727,054 | 712,889 | 438,091 | |
| Accumulated other comprehensive income (loss) | -505 | 145 | -76 | |
| Accumulated deficit | -255,085 | -201,465 | -174,540 | |
| Total stockholders' equity | 471,512 | 511,617 | 263,512 | |
| Total liabilities and stockholders' equity | 497,597 | 535,323 | 285,495 | |
Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc. (RAPP)